NCT04410133
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have had previous radiation therapy of brain metastatic lesion(s)
Exclusions:
https://ClinicalTrials.gov/show/NCT04410133